The short version of Mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
== Modulators == Dihexa is an orally active, centrally penetrant small-molecule compound that directly binds to HGF and potentiates its ability to activate its receptor, c-Met. It is a strong inducer of neurogenesis and is being studied for the potential treatment of Alzheimer's disease and Parkinson's disease.
The following table is based on the ISSCAAP classification (International Standard Statistical Classification of Aquatic Animals and Plants) used by the FAO to collect and compile fishery statistics. The production figures have been extracted from the FAO FishStat database, and include both capture from wild fisheries and aquaculture production.
In Asia, two species, in particular, are widely harvested: Korean pine (Pinus koraiensis) in northeast Asia (the most important species in international trade) and chilgoza pine (P. gerardiana) in the western Himalaya. Four other species, Siberian pine (P. sibirica), Siberian dwarf pine (P. pumila), Chinese white pine (P. armandii) and lacebark pine (P. bungeana), are also used to a lesser extent. Russia is the largest producer of P. sibirica nuts in the world, followed by either Mongolia or Afghanistan. They each produce over 10,000 metric tons (9,800 long tons; 11,000 short tons) annually, most of it exported to China. Pine nuts produced in Europe mostly come from the stone pine (P. pinea), which has been cultivated for its nuts for over 5,000 years. Pine nuts have been harvested from wild trees for far longer. The Swiss pine (P. cembra) is also used, to a very small extent. In North America, the main species are three of the pinyon pines: Colorado pinyon (P. edulis), single-leaf pinyon (P. monophylla), and Mexican pinyon (P. cembroides). The other eight pinyon species are used to a small extent, as are gray pine (P. sabineana), Coulter pine (P. coulteri), Torrey pine (P. torreyana), sugar pine (P. lambertiana) and Parry pinyon (P. quadrifolia). Here, the nuts themselves are known by the Spanish name for the pinyon pine, piñón (plural: piñones).
It also is based on the finding that insulin resistance may be reversed rapidly by exposing cells to mitochondrial uncouplers, electron transport chain inhibitors, or mitochondrial superoxide dismutase mimetics.
== Biological activity == In humans, melatonin is presumed to act as a full agonist of two types of melatonin receptors: melatonin receptor 1, with picomolar binding affinity, and melatonin receptor 2, with nanomolar binding affinity. Both receptors are part of the G-protein coupled receptors (GPCRs) family, specifically the Gi/o alpha subunit GPCRs. In vitro, melatonin functions as a high-capacity antioxidant or free radical scavenger within mitochondria, playing a dual role in combating cellular oxidative stress. First, it directly neutralizes free radicals, and second, it promotes the gene expression of essential antioxidant enzymes, such as superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase. This increase in antioxidant enzyme expression is mediated through signal transduction pathways activated by the binding of melatonin to its receptors. Through these mechanisms, melatonin is presumed to protect cells against oxidative stress in ways beyond regulating the sleep-wake cycle.
Sources: en.wikipedia.org
Niosomes are vesicles composed of non-ionic surfactants, incorporating cholesterol as an excipient. Niosomes are utilized for drug delivery to specific sites to achieve desired therapeutic effects. Structurally, niosomes are similar to liposomes as both consist of a lipid bilayer. However, niosomes are more stable than liposomes during formation processes and storage. Niosomes trap hydrophilic and lipophilic drugs, either in an aqueous compartment (for hydrophilic drugs) or in a vesicular membrane compartment composed of lipid material (for lipophilic drugs).
== Mechanism == According to later research on its mechanism of action, α-bungarotoxin binds irreversibly to the postsynaptic nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction. It inhibits the action of acetylcholine competitively, leading to respiratory failure, paralysis and even death. α-bungarotoxin specifically targets the nervous system, interfering with the nerve impulse transmission. The primary target of the toxin is the neuromuscular junction of skeletal muscles, where the motor nerve terminal and the nicotinic acetylcholine receptor are the major target sites. Their neurotoxic effect is often referred to as resistant neurotoxicity. This is because of the damage caused to nerve terminals that leads to acetylcholine depletion at the neuromuscular junction. The regeneration of the synapses can take days, which prolongs the paralysis and recovery process for the victim. In addition, the severity of the paralysis ranges from mild to life-threatening depending on the degree of envenomation, its composition and the early therapeutic intervention.
=== Medical === As an antipruritic to reduce itching. As a topical analgesic, it is used to relieve minor aches and pains, such as muscle cramps, sprains, headaches and similar conditions, alone or combined with chemicals such as camphor, eucalyptus oil or capsaicin. In Europe, it tends to appear as a gel or a cream, while in the U.S., patches and body sleeves are very frequently used, e.g.: Tiger Balm, or IcyHot patches or knee/elbow sleeves. As a penetration enhancer in transdermal drug delivery. Used to cause a subjective feeling of decongestion in nasal inhalers. In decongestants for chest creams and patches. Examples: Vicks VapoRub, Mentholatum, Axe Brand, VapoRem, Mentisan. In certain medications used to treat sunburns, as it provides a cooling sensation (then often associated with aloe). Commonly used in oral hygiene products and bad-breath remedies, such as mouthwash, toothpaste, mouth and tongue sprays, and more generally as a food flavor agent; such as in chewing gum and candy. In first aid products such as "mineral ice" to produce a cooling effect as a substitute for real ice in the absence of water or electricity (pouch, body patch/sleeve or cream). In nonprescription products for short-term relief of minor sore throat and minor mouth or throat irritation e.g.: lip balms and cough medicines.
== Applications == Aerogels are used in a wide range of applications because of their low density, low thermal conductivity, and high surface area. Silica aerogels were the first to be developed commercially and remain the most widely used type. Flexible polymer-based aerogels have been developed to overcome the brittleness of traditional silica aerogels and enable thin, mechanically compliant insulating materials for aerospace and electronic systems. Polyimide aerogel films derived from NASA-developed aerogel technology have been commercialized for such applications; examples include the polyimide aerogel film AeroZero.
=== Safety controversies and fraud === FDA staffers publicly complained that safety problems and some data integrity issues were ignored prior to approval, and the House Committee on Energy and Commerce held hearings to examine these complaints. One doctor went to prison because she falsified data in her portion of the clinical trials (about 400 patients out of 24,000). Further, Ketek seemed to cause liver problems, including "liver failure", to a greater extent than would be expected of a common-use antibiotic. The House Committee on Energy and Commerce held hearings. Study 3014 was a key clinical trial of approximately 24,000 patients which Sanofi-Aventis submitted to the FDA to seek approval for Ketek. The doctor who treated the most patients in Study 3014 (about 400), Maria "Anne" Kirkman Campbell, served a 57-month sentence in federal prison after pleading guilty to mail fraud, by defrauding Aventis and others. The indictment states that Campbell fabricated data she sent to the company. Documents, including internal Sanofi-Aventis emails show that Aventis was worried about Campbell early in study 3014 but didn't tell the FDA until the agency's own inspectors discovered the problem independently. In January 2006, an article in the March issue of Annals of Internal Medicine was published, citing three recent drug-induced liver injury cases likely due to telithromycin, one resulting in a liver transplant and one in death.
Sources: en.wikipedia.org
Since then, the clinic has had 235 beds, including 10 designated for the anti-rabies service. From 1973 to 1975, renovations were carried out on the old pavilion, with the introduction of central heating and hot and cold water in each ward, and heating was switched to methane gas. By separating a 28-bed ward, space for the intensive care unit was created, starting in Ward I on 9 April 1975, and in Ward II on 1 February 1978. From December 1974 to June 1976, a new pavilion was constructed to serve as a clinical laboratory (the new Infectious Diseases building), which became operational on 1 March 1977, under the leadership of Jema Lacint.
=== Loss of solubility === When proteins are folded, they fold so as to keep their hydrophobic parts on the inside (away from water) and their hydrophilic parts on the outside (contacting the water). This makes them soluble enough not to precipitate. However, when denatured the surface of the protein is partly hydrophobic and partly hydrophilic (as it no longer has an "inside" in which to hide the hydrophobic parts), causing it to become insoluble in water. The hydrophobic parts of the denatured proteins stick together, forming a network (gel): this is called coagulation. The coagulation of denatured proteins is the reason eggs solidify when cooked. When acid is added to milk, the protein casein denatures and coagulates (with fat and water inclusions from the milk) into curds, the first step in making cheese; although milk can also be made to curdle (i.e. casein to coagulate) by other methods, for example the addition of enzymes like chymosin.
== See also == AH-7921 Bezitramide Cebranopadol Deekonda2016 Diphenpipenol DPI-3290 Etazen GSK1702934A J-113,397 Oliceridine PZM21 R6890 SR-14968 SR-16435 SR-17018 List of fentanyl analogues List of orphine opioids
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares. It is a human monoclonal antibody targeted at interleukin-1β. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha. Common side effects include infections (colds and upper respiratory tract infections), abdominal pain and injection-site reactions.
Most pesticides protect crops against insects and plants, but in some cases antimicrobial pesticides are used to protect against various microorganisms such as bacteria, viruses, fungi, algae, and protozoa. The overuse of many pesticides in an effort to have a higher yield of crops has resulted in many of these microbes evolving a tolerance against these antimicrobial agents. Currently there are over 4000 antimicrobial pesticides registered with the US Environmental Protection Agency (EPA) and sold to market, showing the widespread use of these agents. It is estimated that for every single meal a person consumes, 0.3 g of pesticides is used, as 90% of all pesticide use is in agriculture. A majority of these products are used to help defend against the spread of infectious diseases, and hopefully protect public health. But out of the large amount of pesticides used, it is also estimated that less than 0.1% of those antimicrobial agents, actually reach their targets. That leaves over 99% of all pesticides used available to contaminate other resources. In soil, air, and water these antimicrobial agents are able to spread, coming in contact with more microorganisms and leading to these microbes evolving mechanisms to tolerate and further resist pesticides. The use of antifungal azole pesticides that drive environmental azole resistance have been linked to azole resistance cases in the clinical setting. The same issues confront the novel antifungal classes (e.g. orotomides) which are again being used in both the clinic and agriculture.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.